Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The global blood screening market is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2%
This report serves as a valuable resource for stakeholders seeking to comprehend the competitive landscape and gain deeper insights to enhance their business positioning. It equips stakeholders with the necessary information to formulate effective go-to-market strategies.
The growth in this market is primarily propelled by the increasing demand for donated blood, a rising number of blood donations worldwide, and the continual prevalence of infectious diseases. However, the high cost of blood screening instruments and kits, coupled with a shortage of skilled technicians, poses potential obstacles to the growth of the Blood screening market.
The report conducts a comprehensive analysis of key industry players, delivering insights into their business profiles, solutions, and services, as well as their key strategies. It also covers contractual agreements, partnerships, collaborations, new product and service launches, mergers and acquisitions, and recent developments within the Blood screening market. Furthermore, the report includes a competitive analysis of emerging startups in the Blood screening market ecosystem.
A thorough assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), and bioMerieux (France), among others, is an integral part of this report's coverage of the blood screening market.
Additionally, the report provides a pulse on the market, offering insights into key drivers, restraints, challenges, and opportunities that shape the landscape.
The reagents & kits segment accounted for the highest growth rate in the blood screening market, by product & service, during the forecast period.
The blood screening market is segmented into reagents & kits, instruments, and software & services based on product.
In 2022, the reagents & kits segment accounted for the highest growth rate in the blood screening market. Market growth can largely be attributed to rising number of blood transfusions and blood donations. In addition, technological advancements in blood screening technologies and the increasing number of surgeries are stimulating the growth of this segment.
Blood banks segment accounted for the highest CAGR.
Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2022, the blood banks segment accounted for the highest growth rate. This can be attributed to the growing number of organ transplantation surgeries, and rising awareness about blood safety.
Asia Pacific: The fastest-growing region blood screening market.
The rising per capita income, the expansion of private hospitals into rural areas in various APAC countries, the rising geriatric population in several APAC countries (coupled with the rising prevalence of chronic disorders), and the presence of high-growth markets in the region, among other factors, all contribute to rising healthcare spending. The favorable regulatory climate and low labor costs in this region are also anticipated to fuel market growth.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 253 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $2.4 Billion |
| Forecasted Market Value (USD) by 2028 | $3.4 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
Premium Insights
- Increasing Number of Blood Donations to Drive Market Growth During Forecast Period
- Reagents & Kits Segment to Dominate Market During Forecast Period
- Nucleic Acid Tests Segment to Dominate Market During Forecast Period
- Blood Banks Segment to Dominate Market During Forecast Period
- Asia-Pacific Region to Register Highest Growth Rate from 2023 to 2028
Case Study Analysis
- Case Study 1: Optimization of Hbsag Quantitative Elisa
- Case Study 2: Clinical Efficacy of Nat with Elisa
Market Dynamics
Drivers
- Increasing Blood Donations
- Rising Prevalence of Infectious Diseases
Restraints
- High Cost of Blood Screening Technologies
Opportunities
- Rising Technological Advancements
- High Growth Potential of Emerging Economies
Challenges
- Usage of Low-Sensitivity Screening Tests
- Shortage of Skilled Laboratory Technicians
Company Profiles
Key Players
- F. Hoffmann-La Roche Ltd.
- Grifols, SA
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Diasorin
- Biomerieux
- Bd
- Danaher (Beckman Coulter, Inc.)
- Hologic, Inc.
- Siemens Healthineers AG
- Thermo Fisher Scientific, Inc.
Other Players
- Ortho Clinical Diagnostics
- Merck KGaA
- Revvity (Part of Perkinelmer Inc.)
- Bio-Techne
- Gfe
- Trinity Biotech
- J. Mitra & Co. Pvt. Ltd.
- Mindray
- Maccura Biotechnology Co. Ltd.
- Immucor, Inc.
- Cellabs
- Abnova Corporation
- Enzo Biochem, Inc.
- Tulip Diagnostics Pvt. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/ky4vkw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
